Lupin gets six observations from USFDA for Indore plant: Report

25 May 2017 Evaluate

Lupin has reportedly received 6 USFDA Form 483 observations for its Indore plant. The facility was inspected by the US drug regulator between May 8 and May 19, 2017.  Earlier, USFDA has issued eight observations for the company’s Aurangabad unit, which was inspected between April 17 and 26, 2017.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2119.50 -31.55 (-1.47%)
01-Feb-2026 13:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.65
Dr. Reddys Lab 1225.20
Cipla 1318.20
Zydus Lifesciences 887.15
Lupin 2119.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×